Diagram illustrating broad recommendations from the EHA/EBMT on evaluation and management of ICAHT. Highlighted components include the use of CAR-HEMATOTOX prior to leukapheresis to determine risk of ICAHT, a new grading system for ICAHT, and diagnostic and therapeutic measures based on the duration and severity of cytopenias. ANC, absolute neutrophil count; BMA, bone marrow aspirate; CBC, complete blood count; G-CSF, granulocyte colony stimulating factor; HLH, hemophagocytic lymphohistiocytosis; MAS, macrophage activation syndrome; TPO, thrombopoetin.